Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 29, 2019

Novartis reports positive results from psoriasis drug trials

Novartis has reported positive results from a pooled analysis of four Phase lll clinical trials evaluating Cosentyx (secukinumab) in patients with moderate-to-severe plaque psoriasis (PsO).

Novartis has reported positive results from a pooled analysis of four Phase III clinical trials evaluating Cosentyx (secukinumab) in patients with moderate-to-severe plaque psoriasis (PsO).

PsO is characterised by painful red, raised, dry patches of skin and usually attacks extensor areas of the forearms and shins as well as the scalp, palms of the hand, soles of the feet and fingernails.

Cosentyx is a fully human IL-17A antagonist approved to treat moderate to severe PsO, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).

The latest analysis showed that patients treated with Cosentyx 300mg achieved improvements in mobility, self-care, and usual activities components as measured by the EQ-5D-3L questionnaire at week four.

“These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance.”

Wake Forest School of Medicine representative Steven Feldman, who receives research support from Novartis, said: “Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life.

“These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The pooled analysis is based on data gained from the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, which enrolled patients with moderate-to-severe psoriasis.

The trials saw 309 patients treated with Cosentyx 300mg and 282 patients receive placebo.

Patients who reported problems with mobility, self-care, or usual activities at baseline were also included in the trial.

The trials compared the percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities at weeks four, eight and 12.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU